Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.

Abstract: Immunomodulatory nanofilaments are provided which present immune factors, especially cytokines, to immune cells, particularly T cells, so as to modulate the immune response of said cells. Methods of using such nanofilaments are also provided.

Abstract: The present disclosure provides polyoxazoline (POx) copolymers which exhibit very high affinity for calcium ions, are capable of forming hydrogels and are bioresorbable. The polyoxazoline copolymers comprise at least 20 oxazoline units, including at least 4 non-terminal oxazoline units that contain a calcium binding group. Methods of making such polyoxazoline copolymers and using them in biomedical applications are also provided.

Abstract: Method of inhibiting a protein-protein interaction between Von Hippel-Lindau tumor-suppressor protein and hypoxia-inducible factor 1-alpha useful in the treatment of angiogenesis-related diseases and promoting wound healing.

Abstract: The present invention provides a composition that controls pharmacokinetics. Specifically, the present invention provides: a composition for controlling pharmacokinetics, the composition containing a polyvalent cation as an active ingredient; and a method for controlling pharmacokinetics using the polyvalent cation.

Abstract: The present disclosure provides a method for preparing a hydrogel composition with thermos-sensitive and ionic reversible properties and the hydrogel composition prepared by the method. Related application products of the hydrogel composition of the present disclosure include wound dressings, drug carriers, three-dimensional cellular scaffolds, soluble microspheres, and cell capture and release systems, wherein the hydrogel composition with thermos-sensitive and ionic reversible properties has good in vitro and in vivo stability and high biocompatibility, and is non-toxic. The hydrogel composition can be removed and replaced by washing with metal chelating aqueous solution at low temperature.

Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.

Abstract: The present invention relates to supramolecular biomedical polymers comprising quadruple hydrogen bonding units and to a process for preparing such a supramolecular biomedical polymer and porous biomedical implants thereof. The supramolecular biomedical polymers are particularly suitable for the production of porous biomedical implants that need high strength, elasticity, durability, and slow biodegradation, e.g. medical implants for living tissue regeneration within a mammal, such as the treatment of cardio-vascular diseases, medical prolapses, and hernias.

Abstract: A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.

Abstract: Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.

Abstract: Polymeric conjugates comprising a polymeric matrix having associated therewith an agent that down-regulates an activity or expression of a polypeptide associated with onset or progression of melanoma, and optionally and preferably, an additional agent that acts in synergy with said agent, are provided. Synthetic methodologies for preparing these conjugates and uses thereof in treating melanoma and other cancerous diseases are also provided.

Abstract: ABA type block copolymers as a new class of temperature sensing polymers with tunable, high temperature coefficient of resistance (TCR). A sensor includes a heater, a thermal insulator between two thermometer layers, the heater generating a thermal gradient within the thermal insulator. The thermometers give an indirect measurement of fluid flow around the sensor, based on their temperature readings. The thermometers are flexible layers including ABA block polymers.

Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.

Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Abstract: A method of making a solution including poly(ethylene terephthalate). The method includes dissolving poly(ethylene terephthalate) in a solvent mixture to form a solution, the solvent mixture including two solvent components. A Hansen Solubility Parameter Distance between the solvent mixture and HSP coordinates having a dispersion HSP of 18.02 MPa0.5, a polar HSP of 5.56 MPa0.5, and a hydrogen bonding HSP of 14.27 MPa0.5 is less than about 2 MPa0.5.

Abstract: Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

Abstract: A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB2 receptor agonist is described. The CB2 receptor agonist can be a compound according to formula I or a pharmaceutically acceptable salt thereof, with R1 and R2 as defined herein. Administration of the CB2 receptor agonist activates CB2 receptors in the microglia, and can restore syntaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-ßpeptide in the brain.

Abstract: The present invention provides an amphiphilic block copolymer for drug delivery and a controlled release system comprising the same copolymer. The copolymer comprises at least one hydrophilic block and at least one hydrophobic block, wherein the hydrophobic block is selected from the group consisting of acrylates, methacrylates, acrylamides, methacrylamides, vinylethers and their aromatic derivatives, wherein at least one hydrophobic block contains an aryl group, which is bound to the hydrophobic block with a degradable linker. The controlled release system of the invention shows high stability and high drug retention when administered in vivo enabling accumulation and drug release at the site of action.

Abstract: The present invention relates to a method for the purification of peptides which are produced by solid phase peptide synthesis (SPPS) and corresponding linker molecules for use in said method.

Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

Abstract: Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.

Abstract: The present disclosure relates to a manufacturing system, method and control circuitry for quality assured manufacturing of at least two biopharmaceutical products. The manufacturing system comprises a warehouse facility, a hydration facility, and at least two biopharmaceutical manufacturing facilities, wherein the warehouse facility and hydration facility are comprised in the macro structure. Each biopharmaceutical manufacturing facility is comprised in a respective micro node, and a control facility in the macro structure is configured to control interoperability of the macro structure and the micro nodes by means of a network spine interconnecting the macro structure with each micro node.

Abstract: In alternative embodiments, the invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino-acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps.

Abstract: A hybrid hydrogel including a hydrogel material and a plurality of first hybrid nanoparticles is provided. The plurality of first hybrid nanoparticles are conjugated to the hydrogel material, wherein each of the first hybrid nanoparticles includes a first positive-charged polysaccharide and a first negative-charged polysaccharide. The first positive-charged polysaccharide is located at an inner core of the first hybrid nanoparticles. The first negative-charged polysaccharide is located at an outer shell of the first hybrid nanoparticles and carries a plurality of first growth factors. The first negative-charged polysaccharide and the first positive-charged polysaccharide are electrostatically attracted to form the first hybrid nanoparticles. A method of fabricating the hybrid hydrogel is also provided.

Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.

Abstract: The presently-disclosed subject matter includes a compound comprising a first monomer, which is allyl-functionalized and crosslinkable, and a second monomer, which is not crosslinkable. In some embodiments the compounds are photocrosslinkable, and in certain embodiments are photocrosslinkable by ultraviolet light. Also provided are shape memory vascular grafts comprised the of present compounds that can transition from a temporary shape to an original shape when heated above a melting temperature of the graft. Still further provided are methods for treating vascular conditions that utilize embodiments of the present grafts.

Abstract: Disclosed are biomimetic imageable polymeric materials that include a polymer or copolymer and a covalently-linked contrasting agent where the disclosed films are both bioresorbable and visible by X-ray fluoroscopic imaging and/or magnetic resonance imaging. The invention also provides methods of preparing the polymeric materials and their use in and as implantable medical devices.

Abstract: The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, ancurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents.

Abstract: The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: A substrate for biochips, in which carboxyl groups are immobilized on a substrate whose surface at least is composed of carbon; and a method for producing the substrate are disclosed. The substrate for biochips comprises a substrate whose surface at least is composed of carbon; and an acrylic polymer having free carboxyl groups in the molecular structure thereof, which acrylic polymer is immobilized on the surface of the substrate. The method for producing the substrate comprises irradiating the substrate whose surface at least is composed of carbon with ultraviolet light during the acrylic polymer having free carboxyl groups in the molecular structure thereof contacts the substrate.

Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.

Abstract: A novel imidazole compound that yields a surface treatment liquid that is very effective at suppressing migration and oxidation of a wiring surface; a metal surface treatment liquid that contains the imidazole compound; a metal surface treatment method that uses the metal surface treatment liquid; and a laminate production method that uses the surface treatment liquid. A metal is surface-treated using the surface treatment liquid which includes a saturated fatty acid or a saturated fatty acid ester of a specific structure, in which a prescribed position is substituted by an aromatic group of a prescribed structure and an imidazolyl group that may have a substituent group.

Abstract: A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling

Abstract: The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived copolymer segment containing a repeating unit derived from an unsaturated monomer containing a carboxylic acid or a carboxylic acid salt as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is 35 to 59% by mass, a content of the repeating unit derived from the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt in the organopolysiloxane graft polymer is 4 to 17% by mass, and a content of a repeating unit derived from an unsaturated monomer whose homopolymer has a glass transition point of not lower than 150° C.

Abstract: Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.

Abstract: A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.

Abstract: The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.

Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Abstract: A process for forming a graphene circuit pattern on an object is described. A graphene layer is grown on a metal foil. A bonding layer is formed on a protective film and a surface of the bonding layer is roughened. The graphene layer is transferred onto the roughened surface of the bonding layer. The protective film is removed and the bonding layer is laminated to a first core dielectric substrate. The metal foil is etched away. Thereafter the graphene layer is etched using oxygen plasma etching to form graphene circuits on the first core dielectric substrate. The first core dielectric substrate having graphene circuits thereon is bonded together with a second core dielectric substrate wherein the graphene circuits are on a side facing the second core dielectric substrate wherein an air gap is left therebetween.

Abstract: Disclosed herein is a method of: treating an organic polymer with an electron beam-generated plasma; exposing the treated polymer to air or an oxygen- and hydrogen-containing gas, generating hydroxyl groups on the surface of the polymer; reacting the surface with an organosilane compound having a chloro, fluoro, or alkoxy group and a functional or reactive group that is less reactive with the surface than the chloro, fluoro, or alkoxy group; and covalently immobilizing a biomolecule to the functional or reactive group or a reaction product thereof.

Abstract: A furan-based polyamide is prepared by the following steps: (1) preparing a furan-based oligomer of formula (1) H2N—R—(NH—CO—F—CO—NH—R)n—NH2 (1) where R is a hydrocarbon moiety and F is a furan (cyclo-C4H2O) moiety and n represents the average degree of oligomerization, and where n is within the range of 1 to 10 by reacting 2,5-furandicarboxylic acid or its derivative with a diamine at a temperature of at most 100° C.; (2) contacting the oligomer of step (1) with a bifunctional linker selected from an acid or a derivative thereof where the acid is furandicarboxylic acid or a non-aromatic dicarboxylic acid; provided that if the hydrocarbon moiety R is aromatic, then the bifunctional linker is an aromatic dicarboxylic acid or a derivative thereof, at a mole ratio of the oligomer to the difunctional linker within the range of 0.8 to 1.5 at polycondensation conditions, and (3) isolating the resulting polyamide.

Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.

Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Abstract: Medical constructs with collagen fibers and gelatin and related collagen fibers. The collagen fibers can be derived from extruded soluble dermal collagen and can include a gelatin film attached to the at least one collagen fiber. The gelatin film can include one or more minerals and has a gelatin concentration of between about 0.1% to about 40% weight per volume.